Raymond James Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
Raymond James analyst Martin Auster reiterated a Buy rating on Scholar Rock Holding today and set a price target of $53.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Auster is a 5-star analyst with an average return of 16.5% and a 51.14% success rate. Auster covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, BridgeBio Pharma, and Disc Medicine.
In addition to Raymond James, Scholar Rock Holding also received a Buy from TD Cowen’s Marc Frahm in a report issued yesterday. However, today, TipRanks – OpenAI reiterated a Hold rating on Scholar Rock Holding (NASDAQ: SRRK).
Based on Scholar Rock Holding’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $102.22 million. In comparison, last year the company had a GAAP net loss of $64.48 million
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRRK in relation to earlier this year. Last month, Srinivas Akkaraju, a Director at SRRK bought 29,599.00 shares for a total of $1,181,633.67.
Read More on SRRK:
Disclaimer & DisclosureReport an Issue
- Scholar Rock Details 2026 Strategy and Regulatory Priorities
- Scholar Rock initiated with a Buy at Citi
- Buy/High Risk: Apitegromab’s Differentiated SMA Profile and Expanding Neuromuscular Upside Support Significant Re-Rating Potential
- Scholar Rock initiated with a Buy at UBS
- Scholar Rock price target raised to $52 from $45 at Barclays
